Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:48:30.248Z.
Calculation as of: 2026-10-06T20:48:30.248Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe2709ba5bee8827173e7eb2406bfc0a2a715a78b0d2155f196b4173acd92065
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$471.57M
EV/FCF Ratio
N/A
TTM Avg
997.52x
3Y Avg
857.93x
5Y Avg
857.93x
Market Cap
$472.23M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$475.91M
EV/FCF Ratio
N/A
TTM Avg
36.88x
3Y Avg
36.88x
5Y Avg
36.88x
Market Cap
$483.54M
EV/FCF Ratio
11.00x
TTM Avg
7.76x
3Y Avg
12.39x
5Y Avg
16.55x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | $469.12M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $467.90M | 17.00x | 21.93x | 76.52x | 57.94x |
| Cerus Corporation (CERS)vs › | $471.57M | N/A | 997.52x | 857.93x | 857.93x |
| Arvinas, Inc. (ARVN)vs › | $471.65M | N/A | 5.27x | 5.30x | 11.22x |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | N/A | N/A | N/A | N/A |
| Sight Sciences, Inc. (SGHT)vs › | $465.75M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | N/A | 36.88x | 36.88x | 36.88x |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 11.00x | 7.76x | 12.39x | 16.55x |
| NRC Health (NRC)vs › | $452.54M | 24.92x | 32.87x | 32.01x | 32.13x |
| Evolus, Inc. (EOLS)vs › | $486.01M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
